NCT01032070 2024-12-12
PETEY
Astellas Pharma Inc
Phase 2 Terminated
Clinical Trials
3 trialsNCT01247922 2024-12-06
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Astellas Pharma Inc
Phase 2 Terminated
NCT02689336 2019-09-09
Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
Washington University School of Medicine
Phase 2 Withdrawn